Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Despite the institution of an interdisciplinary Inflammatory Bowel Disease (IBD) centre is encouraged, how it may improve patient care is still unknown. In a 5-year period following organisation of an IBD centre, hospitalisations per patient/year decreased (0.41-0.17) and patients on biologics increased (7.7%-26.7%). Total number of hospitalisations (-18.4%) and length of hospitalisation (-29.4%) improved compared with a preceding 5-year period. These findings suggest that institution of an interdisciplinary IBD centre is associated with improved healthcare utilisation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/eci.14143 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Intestinal taurine acts as a novel immunometabolic modulator of IBD by degrading redundant mitochondrial RNA.
Cell Mol Immunol
September 2025
Department of Gastroenterology, Sir Run Run Shaw Hospital, College of Medicine Zhejiang University, Hangzhou, China.
Anti-tumor necrosis factor (TNF) therapy for inflammatory bowel disease (IBD) is hampered by issues of nonresponse and resistance, highlighting the urgent need for alternative or complementary treatments. Our study revealed significant upregulation of taurine in the intestinal tissues of IBD patients, which was inversely related to the severity of the disease. A key discovery was that TNF directly induced taurine synthesis in intestinal epithelial cells and increased the production of angiogenin, a nuclease that degrades mitochondrial RNA, which is known to amplify inflammatory responses.
View Article and Find Full Text PDFOvercoming anti-Infliximab antibodies and maintaining Infliximab achieves superior durability and outcome compared to switching to Adalimumab.
Dig Liver Dis
September 2025
Division of Pediatric Gastroenterology and Nutrition, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Tel-Hashomer, Israel; The Gray Faculty of Medical and Health Sciences, Tel-Aviv University, Tel-Aviv, Israel; Cincinnati Children's Hospital Medical Center and the University of Cin
Background And Aims: The development of antibodies to infliximab (ATI) is a major challenge in pediatric inflammatory bowel disease (IBD). This real-world study aimed to identify predictors of ATI, evaluate strategies to overcome ATI, and compare the durability of continuing infliximab (IFX) versus switching to adalimumab (ADA) after ATI development.
Methods: We retrospectively analyzed 194 pediatric IBD patients treated with IFX from 2010 to 2024.
Fatigue in patients with Inflammatory Bowel Disease: a descriptive cross-sectional study.
Gastroenterol Hepatol
September 2025
Centro de Enfermedades Inflamatorias Mediadas por la Inmunidad (CEIMI) Hospital General Universitario Gregorio Marañón, Calle Francisco Silvela 40, 28028 Madrid, España; Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Calle del Doctor Esquerdo nº 46, 28009 Madrid, España; Depa
Aim: To identify factors associated with the presence of fatigue in patients with inflammatory bowel disease.
Patients And Method: Prospective cross-sectional descriptive study conducted in a multidisciplinary centre for the treatment of EIMI. Participants were patients diagnosed with IBD under follow-up in an advanced practice nurse (APN) consultation.
Natural Products for Regulation of Autoimmune Diseases: Chemical Diversity, Pharmacology, and Therapeutic Applications.
Chem Biodivers
September 2025
Zhejiang Provincial Engineering Research Center of New Technologies and Applications for Targeted Therapy of Major Diseases, Laboratory of Anti-Allergy Functional Compounds, College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou, China.
Autoimmune diseases (AIDs), defined by irregularities in immune system function, pose a substantial health challenge worldwide, impacting millions with persistent and frequently debilitating conditions. Conventional treatments, such as glucocorticoid-based immunosuppressive therapies, are associated with notable drawbacks and limitations. In response to these difficulties, recent scientific efforts have increasingly focused on natural compounds as potential therapeutic agents.
View Article and Find Full Text PDFSarcopenia-A Valuable Imaging Biomarker for Disease Progression in Patients With Primary Sclerosing Cholangitis (PSC)?
Liver Int
October 2025
Hannover Medical School, Department of Diagnostic and Interventional Radiology, Hannover, Germany.
Background And Aims: We aimed to ascertain the prevalence of sarcopenia in patients with primary sclerosing cholangitis (PSC) and to assess the prognostic value as a biomarker for disease outcome.
Methods: We collected data from 224 patients (148 male, 76 female; mean age 41 years) from January 2002 to December 2021, with a confirmed diagnosis of PSC who underwent magnetic resonance imaging (MRI). Muscle mass was quantified at the level of the third lumbar vertebra by measurement of psoas muscle thickness (PMT) and total psoas muscle area (PMA).